Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug composition resisting influenza virus A or enterovirus

A technology of influenza virus and enterovirus, applied in antiviral agents, medical raw materials derived from fungi, etc.

Active Publication Date: 2012-10-31
NEW BELLUS ENTERPRISES
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there is no special medication or vaccine for enterovirus infection, and supportive therapy is often used for treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composition resisting influenza virus A or enterovirus
  • Drug composition resisting influenza virus A or enterovirus
  • Drug composition resisting influenza virus A or enterovirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Fermentation broth AC1 and its mycelium AC1F:

[0047] 1. AC1 sub-extraction steps:

[0048] a: Put AC1 into a beaker, add 20 times the volume of M.Q water to redissolve, and pour it into a separatory funnel;

[0049] b: Add an equal volume of ethyl acetate (EA, which has been saturated with water) for partition. After the layers are separated, take out the upper layer (ie, the EA layer), and add an equal volume of water-saturated layer to the lower layer (ie, the water layer) EA continued to be sub-extracted, and after a total of 5 extractions, the 5 EA layers were combined and concentrated to obtain the EA layer sub-extract (AC1-LPEA);

[0050] c: The water layer after the EA fractionation continues to be sub-extracted with an equal volume of n-butanol (n-BuOH, which has been saturated with water), the method is the same as b, but the final combined n-butanol layer needs to be separated with an equal volume of n-butanol M.Q. water back extraction once, so that its n...

Embodiment 2

[0076] Fermentation broth AC2 and its mycelium AC2F

[0077] 1. AC2 sub-extraction steps:

[0078] a. Weigh AC2 in a beaker, add 20 times the volume of M.Q water to redissolve, and pour it into a separatory funnel.

[0079] b. Add an equal volume of EA (which has been saturated with water) for partitioning. After the layers are separated, take out the upper layer (ie, the EA layer), and add an equal volume of water-saturated EA to the lower layer (ie, the water layer) to continue the partition. After a total of 5 extractions, the 5 EA layers were combined and concentrated to obtain the EA layer sub-extract (AC2-LPEA).

[0080] c. The water layer after the EA fractionation continues to be sub-extracted with an equal volume of n-butanol (which has been saturated with water), the method is the same as b, but the final combined n-butanol layer needs to be back-extracted with an equal volume of M.Q. water Once, in this way, its n-butanol layer fraction (AC2-LPBU) can be obtained....

Embodiment 3

[0136] Fermentation broth AC3 and its mycelium AC3F:

[0137] AC3 fermentation broth and its mycelium extraction steps and process are the same as AC1.

[0138] 1. Antiviral activity test results: H1N1, H3N2 and EV71.

[0139] a.H1N1:

[0140]

[0141] b.H3N2:

[0142]

[0143] c. EV71:

[0144]

[0145] 2. Results:

[0146] a. AC3 has anti-H1N1 activity at a concentration of 200 μg / mL, but has no anti-H3N2 and EV71 activity.

[0147] b. The aqueous layer (AC1-LPWA) after AC3 fractionation has no activity; the EA layer (AC3-LPEA) has anti-H1N1 (50 μg / mL), H3N2 (50 μg / mL) and EV71 (100 μg / mL) activity; positive The butanol layer (AC3-LPBU) has anti-H1N1 (25μg / mL) and anti-EV71 (100μg / mL) activities, but has no activity against H3N2.

[0148] c. Directly extracted with EA, the fermentation broth AC3-EA has strong anti-H1N1 (100μg / mL) and EV71 (6.25μg / mL) activity, and has a slight anti-H3N2 (200μg / mL) activity, while mycelia AC3F-EA has anti-H1N1 (25 μg / mL) and E...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antivirulent drug composition which contains an effective dosage of antrodia camphorata extractive, wherein the antrodia camphorate extractive can be antrodia camphorata zymotic liquor or antrodia camphorate mycelium extract liquor, and the antrodia camphorate extractive is obtained by extracting through an organic solvent. According to the invention, the virus can be influenza virus A (H1N1or H3N2), or an enterovirus (EV71).

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition against type A influenza virus or enterovirus. Background technique [0002] Antrodia camphorate [(Antrodia camphorate) (Zang&Su; S.-H Wu; Ryvaren&T.T.Chang)], also known as camphor mushroom, is a precious medicinal fungus that belongs to Taiwan’s national treasure and is often used for health care. Generally, Antrodia camphorata is called Antrodia camphorata, Zhang Nei mushroom, Antrodia camphorata, Antrodia cinnamomea, Red camphor or Red Antrodia. It is a unique species of mushroom in Taiwan. It only grows in mountainous areas of Taiwan at an altitude of 450-1500 meters in the world. The inner walls of the rotten heartwood of the camphor tree trunks or the dark and damp surface of the dead and lodging camphor wood are very precious and rare, so they are also called "the gems in Taiwan's forests". The polyols contained in Antrodia camphorata can activ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/06A61P31/14A61P31/16
Inventor 赖宗贤钟玉山黄俊智叶思见
Owner NEW BELLUS ENTERPRISES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com